Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference

HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference taking place May 2 and 3, 2016 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Triumvira is scheduled to present on Tuesday, May 3 at 11:30AM ET in Sheraton Hall A.

Dr. Fiorino will provide an overview of Triumvira's progress and future development plans for its T Cell-Antigen Coupler (TAC) technology platform. Since its founding in June 2015, Triumvira has made important strides in bringing this novel and innovative technology forward:

• June 2015. Signed a license and sponsored research agreement with McMaster University in Hamilton, Ontario for the TAC technology.
• October 2015. Completed C$1.8 million financing round.
• December 2015. Appointed Tony Fiorino, MD, PhD as President and Chief Executive Officer.
• January 2016. Appointed Jonathan Bramson, PhD, as Chief Scientific Officer and Christopher Helsen, PhD as Head of Platform Development.
• February 2016. Presented preclinical results at the Translational Research Cancer Centers Consortium Annual Meeting.

At the conference, Dr. Fiorino will review important preclinical data that distinguish TAC-T cells from other engineered T cells and discuss development plans for the company's two lead programs.

About Triumvira Immunologics Inc. 

Triumvira Immunologics Inc. is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Triumvira's innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology and regulated activation of TAC-T cells. Triumvira has licensed the TAC technology from McMaster University in Hamilton, Ontario and its goal is to begin human testing of TAC-T cells by the end of 2017. 

About Bloom Burton & Co. and the Healthcare Investor Conference

Bloom Burton & Co. is a firm dedicated to accelerating returns in healthcare for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton & Co. Limited is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).

Bloom Burton's fifth annual Healthcare Investor Conference will feature approximately 60 of Canada's premier publicly traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event attracts Canadian, U.S. and international investors who are interested in the latest developments in Canadian healthcare companies. Please visit www.bloomburton.com to learn more.